FDA Accepts Application for RSV Vaccine for Infants

The Asthma and Allergy Foundation of America (AAFA) is sharing this press release from Sanofi to bring you the latest research news. [PRESS RELEASE] FDA accepts nirsevimab application as first protective option against RSV disease for all infants FDA accepts nirsevimab application as first protective option against RSV disease for all infants Nirsevimab would be the first broadly protective option against RSV disease designed for all infants, if approved Nirsevimab delivered consistent…

Lesen Sie weiter auf: FDA Accepts Application for RSV Vaccine for Infants
Quelle: Asthma and Allergy Foundation of America
Titelbild/Grafik by Asthma and Allergy Foundation of America (AAFA)

Kommentare und Fragen

Möchten Sie zu diesem Artikel ein Kommentar abgeben oder haben Sie dazu eine Frage, dann machen Sie dies bitte immer auf der Herausgeberseite!

Weiteres von Asthma and Allergy Foundation of America

• FDA Approves Under-the-Tongue Allergen Tablet to Treat Dust Mite Allergy in Children Ages 12-17
• Gifts to Give People With Asthma and Allergies
• FDA Accepts Application for RSV Vaccine for Infants
• A New Look to Better Serve Families Living With Food Allergies
• Tree Pollen: Spring’s First Allergy Offender
• FDA Approves AIRSUPRA, a New Quick-Relief Medicine for Adults with Moderate-to-Severe Asthma
• Understanding and Managing Exercise and Asthma
• 504 Plans to Accommodate Children’s Asthma or Allergies at School
• Building the Foundation for 2023
• 2022 Advocacy for Asthma and Allergies: a Year in Review